At a glance
ClinicalIndex Comparison RecordPhase 4Terminated· 20 enrolled
Drug / intervention
Ibandronate (Bondronat)drug
Likely dose
Ibandronate (Bondronat) 6mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized Study to Evaluate the Safety and Efficacy of Loading Dose of Bondronat Versus Standard Dose of Bondronat in Patients With Lung Cancer and Skeletal Metastasis Experiencing Moderate to Severe Pain
In Brief
A Phase 4 clinical trial evaluating Ibandronate (Bondronat) for Lung Cancer. Terminated early, enrolled 20 participants across 8 sites.
Signals
Trial was terminated early
Detailed Summary
The objective of this trial is to assess the efficacy and safety of loading doses versus standard dose of intravenous Bondronat in reducing pain in patients with lung cancer and bone metastatic disease.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLung Cancer
CountriesChina
Collaborators--
Timeline
Phase 4TerminatedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 2007
Enrollment StartJul 2007
Primary CompletionJan 2008
Study CompletionJul 2008
TodayJul 2026
First PostedJun 27, 2007
Enrollment StartJul 1, 2007
Primary CompletionJan 1, 2008
Study CompletionJul 1, 2008
TodayJul 1, 2026
Enrollment to primary: 6 monthsPosted 19.0 years ago
Interventions
Ibandronate (Bondronat)drug
Intravenous infusion of either 6mg Bondronat on three consecutive days or 6mg Bondronat on one day.